Researchers at CRCHUM and the University of Montreal in Canada discovered a previously unknown link between amyotrophic lateral sclerosis (ALS) neurodegeneration and the immune system. The study was recently published in the journal Nature Communications and is entitled “Neurodegeneration in C. elegans models…
News
Cytokinetics, a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics, and The ALS Association recently announced a collaboration in which Cytokinetics will provide Platinum Level Sponsorship and Gold Level Sponsorship of the National Walks to Defeat ALS for ALS Association Golden West Chapter…
Dr. Ivan Dikic at Goethe University, Frankfurt, Germany has been involved in two groundbreaking studies focusing on molecular details underlying neurodegenerative diseases. The studies were conducted by international research teams and were recently published in the journals Nature Neuroscience – “Haploinsufficiency of TBK1 causes familial…
A new study recently published in the journal PNAS revealed that a new cellular mechanism involving a key protein called hUPF1 can be exploited as a therapeutic strategy for amyotrophic lateral sclerosis (ALS). The study is entitled “Amelioration of toxicity in neuronal models of…
A new study entitled “Syringe-injectable electronics” recently published in the journal Nature Nanotechnology revealed an innovative method to employ tiny electronic devices in the brain, or other parts of the body, as a potential therapy for a wide range of disorders, including neurodegenerative diseases…
Researchers from the University of Toronto (UT) have recently discovered a potential way to detect a genetic predisposition for Amyotrophic Lateral Sclerosis (ALS), before the debilitating symptoms of the disease begin. The study, entitled, “Jump from Pre-mutation to Pathologic Expansion in C9orf72,” was published in the…
Q Therapeutics, Inc., a clinical-stage company committed to find new therapies that might address central nervous system (CNS) diseases, has recently announced that the United States Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) so that Q-Cells’ Phase 1/2a trials can be initiated in patients with amyotrophic lateral sclerosis (ALS). ALS,…
News
Q Therapeutics Announces FDA Clearance of Its Stem Cell Therapy Q-Cells for Human Trials in ALS
Q Therapeutics, Inc., a company focused on adult stem cell therapies for disorders of the central nervous system, recently announced that its product Q-Cells® has received Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) for the start of Phase 1/2a clinical trials in…
Sigma-Aldrich Corporation recently announced it has established an agreement with XCell Science to launch genetically engineered human neural differentiated cells and the corresponding culture media to advance research in the neurological diseases field. Together with the product portfolio of Sigma-Aldrich, these new products offer unique tools relevant for the…
In a recent study published in the journal BMC Neurology researchers found that despite the lack of a curative therapy, Amyotrophic Lateral Sclerosis carergivers (including specialized physicians as well as nursing and familial caregivers) can substantially contribute to the maintenance of quality of life (QoL) at the…
Recent Posts
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’
- Higher blood lactate levels tied to survival, weight changes in ALS
- AB Science adds new biomarker to Phase 3 masitinib ALS clinical trial